Blood volumes required for analytical procedures during the HIPS study
| Blood sample analytics . | Sampled blood volume, mL* . |
|---|---|
| Screening and baseline samples | |
| FVIII activity in plasma | 1.8 |
| Transcriptome profiling in PBMCs after short-term in vitro stimulation with FVIII; FVIII-specific antibody analytics | 4.0 |
| Epigenetic immune cell counting; whole-blood transcriptome profiling | 2.0 |
| Post-FVIII exposure samples | |
| FVIII inhibitor testing; whole-genome profiling (once); FVIII mutation analysis (once) | 2.7 |
| Transcriptome profiling in PBMCs after short-term in vitro stimulation with FVIII; FVIII-specific antibody analytics | 4.0 |
| Epigenetic immune cell counting; whole-blood transcriptome profiling | 2.0 |
| Blood sample analytics . | Sampled blood volume, mL* . |
|---|---|
| Screening and baseline samples | |
| FVIII activity in plasma | 1.8 |
| Transcriptome profiling in PBMCs after short-term in vitro stimulation with FVIII; FVIII-specific antibody analytics | 4.0 |
| Epigenetic immune cell counting; whole-blood transcriptome profiling | 2.0 |
| Post-FVIII exposure samples | |
| FVIII inhibitor testing; whole-genome profiling (once); FVIII mutation analysis (once) | 2.7 |
| Transcriptome profiling in PBMCs after short-term in vitro stimulation with FVIII; FVIII-specific antibody analytics | 4.0 |
| Epigenetic immune cell counting; whole-blood transcriptome profiling | 2.0 |
PBMC, peripheral blood mononuclear cell.
The total blood volume sampled did not exceed 8 mL/kg body weight at any month during the study